Differences between treatment groups in the change in primary outcome measures during the four weeks after discontinuation of study therapy (after adjustment for baseline values)
| Difference from placebo | Difference from budesonide 3 mg | Difference from budesonide 9 mg | ||||
|---|---|---|---|---|---|---|
| Budesonide 3 mg | Budesonide 9 mg | Prednisolone 7.5 mg | Budesonide 9 mg | Prednisolone 7.5 mg | Prednisolone 7.5 mg | |
| Patients for whom 12 and 16 week data were available in each group: placebo, 24; budesonide 3 mg, 30; budesonide 9 mg, 31; prednisolone 7.5 mg, 37. | ||||||
| *p<0.05, **p<0.01. | ||||||
| Tender joint count | 3.967* | 4.699* | 6.423** | −0.732 | −2.457 | −1.725 |
| Swollen joint count | 3.858** | 4.012** | 4.679** | −0.154 | −0.821 | −0.667 |